Literature DB >> 31395958

Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects.

Aline de Oliveira Magalhães Mourão1, Karina Braga Gomes2, Edna Afonso Reis2,3, Renan Pedra de Souza4, Emílio Itamar de Freitas Campos1, Daniel Dias Ribeiro5, Manoel Otávio da Costa Rocha1,5, Maria Auxiliadora Parreiras Martins6,7,8.   

Abstract

Warfarin exhibits a wide variation in dose requirements. We sought to evaluate the association of polymorphisms CYP2C9*2 (rs1799853), CYP2C9*3 (rs1075910), and VKORC1-G1639A (rs9923231) and nongenetic factors with maintenance doses of warfarin <17.5 mg/week and to create an algorithm to predict drug sensitivity. This is a retrospective cohort study including 312 patients assisted at an anticoagulation clinic in Brazil. The mean age of participants was 60.4 ± 13.5 years and 59.9% were female. The logistic regression model included: age [odds ratio (OR) 1.03, 95% confidence interval (CI) 1.01-1.06], genotype VKORC1 AA (OR 31.61, 95% CI 11.20-100.15) and genotype CYP2C9 2/2, 2/3 or 3/3 (OR 16.48, 95% CI 3.37-81.79). The creation of our algorithm involved warfarin-experienced patients on stable doses, identifying factors associated with drug sensitivity. The validation of this algorithm allows its use in future populations to determine the initial dose distinguishing patients with dose requirements <17.5 mg and reducing time to achieve stable doses.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31395958     DOI: 10.1038/s41397-019-0091-3

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  35 in total

Review 1.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study.

Authors:  Vanessa Cristina de Oliveira Almeida; Daniel Dias Ribeiro; Karina Braga Gomes; Ana Lúcia Brunialti Godard
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

3.  A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).

Authors:  Jeffrey L Anderson; Benjamin D Horne; Scott M Stevens; Scott C Woller; Kent M Samuelson; Justin W Mansfield; Michelle Robinson; Stephanie Barton; Kim Brunisholz; Chrissa P Mower; John A Huntinghouse; Jeffrey S Rollo; Dustin Siler; Tami L Bair; Stacey Knight; Joseph B Muhlestein; John F Carlquist
Journal:  Circulation       Date:  2012-03-19       Impact factor: 29.690

Review 4.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.

Authors:  J A Johnson; L Gong; M Whirl-Carrillo; B F Gage; S A Scott; C M Stein; J L Anderson; S E Kimmel; M T M Lee; M Pirmohamed; M Wadelius; T E Klein; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2011-09-07       Impact factor: 6.875

Review 5.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

Authors:  Craig R Lee; Joyce A Goldstein; John A Pieper
Journal:  Pharmacogenetics       Date:  2002-04

6.  Evaluation of genetic factors for warfarin dose prediction.

Authors:  Michael D Caldwell; Richard L Berg; Kai Qi Zhang; Ingrid Glurich; John R Schmelzer; Steven H Yale; Humberto J Vidaillet; James K Burmester
Journal:  Clin Med Res       Date:  2007-03

7.  The largest prospective warfarin-treated cohort supports genetic forecasting.

Authors:  Mia Wadelius; Leslie Y Chen; Jonatan D Lindh; Niclas Eriksson; Mohammed J R Ghori; Suzannah Bumpstead; Lennart Holm; Ralph McGinnis; Anders Rane; Panos Deloukas
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

8.  Identification of the gene for vitamin K epoxide reductase.

Authors:  Tao Li; Chun-Yun Chang; Da-Yun Jin; Pen-Jen Lin; Anastasia Khvorova; Darrel W Stafford
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

9.  A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

Authors:  Fumihiko Takeuchi; Ralph McGinnis; Stephane Bourgeois; Chris Barnes; Niclas Eriksson; Nicole Soranzo; Pamela Whittaker; Venkatesh Ranganath; Vasudev Kumanduri; William McLaren; Lennart Holm; Jonatan Lindh; Anders Rane; Mia Wadelius; Panos Deloukas
Journal:  PLoS Genet       Date:  2009-03-20       Impact factor: 5.917

10.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

View more
  4 in total

Review 1.  Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.

Authors:  Thiago Dominguez Crespo Hirata; Carolina Dagli-Hernandez; Fabiana Dalla Vecchia Genvigir; Volker Martin Lauschke; Yitian Zhou; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Mol Diagn Ther       Date:  2021-08-06       Impact factor: 4.074

2.  Factors Affecting Medication Adherence in Patients with Mechanical Heart Valves Taking Warfarin: The Role of Knowledge on Warfarin, Medication Belief, Depression, and Self-Efficacy.

Authors:  Soohyun Park; Insil Jang
Journal:  Int J Environ Res Public Health       Date:  2021-05-14       Impact factor: 3.390

3.  Instruments for the assessment of patient adherence to oral anticoagulation with warfarin protocol for a systematic review.

Authors:  Marcus Fernando da Silva Praxedes; Mayara Sousa Vianna; Waleska Jaclyn Freitas Nunes de Sousa; Frederico Bartolazzi; Vânia Eloisa de Araújo; Maria Auxiliadora Parreiras Martins
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

Review 4.  Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation.

Authors:  Volker M Lauschke; Magnus Ingelman-Sundberg
Journal:  NPJ Genom Med       Date:  2020-03-05       Impact factor: 8.617

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.